Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?

被引：22
作者：
Barosi, G. [1 ]
Zhang, M-J [2 ]
Gale, R. Peter [3 ]
机构：
[1] Matteo Fdn, IRCCS Policlinico S, Ctr Study Myelofibrosis, Pavia, Italy
[2] Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA
[3] Univ London Imperial Coll Sci Technol & Med, Haematol Res Ctr, Dept Med, Div Expt Med, London, England
来源：
LEUKEMIA | 2014年 / 28卷 / 11期
关键词：
AVAILABLE THERAPY; EFFICACY; SAFETY; INHIBITOR; TRIALS;
D O I：
10.1038/leu.2014.220
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2267 / 2270
页数：5
相关论文
共 15 条
[1]   Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis [J].
Cervantes, Francisco ;
Vannucchi, Alessandro M. ;
Kiladjian, Jean-Jacques ;
Al-Ali, Haifa Kathrin ;
Sirulnik, Andres ;
Stalbovskaya, Viktoriya ;
McQuitty, Mari ;
Hunter, Deborah S. ;
Levy, Richard S. ;
Passamonti, Francesco ;
Barbui, Tiziano ;
Barosi, Giovanni ;
Harrison, Claire N. ;
Knoops, Laurent ;
Gisslinger, Heinz .
BLOOD, 2013, 122 (25) :4047-4053
[2]   JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis [J].
Harrison, Claire ;
Kiladjian, Jean-Jacques ;
Al-Ali, Haifa Kathrin ;
Gisslinger, Heinz ;
Waltzman, Roger ;
Stalbovskaya, Viktoriya ;
McQuitty, Mari ;
Hunter, Deborah S. ;
Levy, Richard ;
Knoops, Laurent ;
Cervantes, Francisco ;
Vannucchi, Alessandro M. ;
Barbui, Tiziano ;
Barosi, Giovanni .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09) :787-798
[3]   Randomized Trials Analyzed as Observational Studies [J].
Hernan, Miguel A. ;
Hernandez-Diaz, Sonia ;
Robins, James M. .
ANNALS OF INTERNAL MEDICINE, 2013, 159 (08) :560-+
[4]   Need to realign patient-oriented and commercial and academic research [J].
Liberati, Alessandro .
LANCET, 2011, 378 (9805) :1777-1778
[5]   The Prevention and Treatment of Missing Data in Clinical Trials [J].
Little, Roderick J. ;
D'Agostino, Ralph ;
Cohen, Michael L. ;
Dickersin, Kay ;
Emerson, Scott S. ;
Farrar, John T. ;
Frangakis, Constantine ;
Hogan, Joseph W. ;
Molenberghs, Geert ;
Murphy, Susan A. ;
Neaton, James D. ;
Rotnitzky, Andrea ;
Scharfstein, Daniel ;
Shih, Weichung J. ;
Siegel, Jay P. ;
Stern, Hal .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (14) :1355-1360
[6]   Hypothesis: How do JAK2-inhibitors work in myelofibfosis [J].
Mesa, Ruben ;
Gale, Robert Peter .
LEUKEMIA RESEARCH, 2009, 33 (09) :1156-1157
[7]   JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations [J].
Pardanani, A. ;
Vannucchi, A. M. ;
Passamonti, F. ;
Cervantes, F. ;
Barbui, T. ;
Tefferi, A. .
LEUKEMIA, 2011, 25 (02) :218-225
[8]   Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts [J].
Passamonti, Francesco ;
Maffioli, Margherita ;
Cervantes, Francisco ;
Vannucchi, Alessandro Maria ;
Morra, Enrica ;
Barbui, Tiziano ;
Caramazza, Domenica ;
Pieri, Lisa ;
Rumi, Elisa ;
Gisslinger, Heinz ;
Knoops, Laurent ;
Kiladjian, Jean Jaques ;
Mora, Barbara ;
Hollaender, Norbert ;
Pascutto, Cristiana ;
Harrison, Claire ;
Cazzola, Mario .
BLOOD, 2014, 123 (12) :1833-1835
[9]   A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) [J].
Passamonti, Francesco ;
Cervantes, Francisco ;
Vannucchi, Alessandro Maria ;
Morra, Enrica ;
Rumi, Elisa ;
Pereira, Arturo ;
Guglielmelli, Paola ;
Pungolino, Ester ;
Caramella, Marianna ;
Maffioli, Margherita ;
Pascutto, Cristiana ;
Lazzarino, Mario ;
Cazzola, Mario ;
Tefferi, Ayalew .
BLOOD, 2010, 115 (09) :1703-1708
[10]   Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis [J].
Tefferi, Ayalew ;
Litzow, Mark R. ;
Pardanani, Animesh .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (15) :1455-1457
12